Send Enquiry
OPTHO
Drops
Packaging and packing Type
| 5ml
MRP :
₹196
PTR :
₹140
PTS :
₹126
A topical ophthalmic combination [corticosteroid/antibiotic] for the management of various ocular surface inflammatory conditions with, or at risk for... Read More
Composition
Send Enquiry
India’s Largest Pharma Franchise
100%
Genuine Products
Secure
Payments
24 x 7
Customer Support
About the product
A topical ophthalmic combination [corticosteroid/antibiotic] for the management of various ocular surface inflammatory conditions with, or at risk for, a bacterial infection. (James E Deom, 2022) An effective ophthalmic suspension for the treatment of ocular inflammation associated with blepharokeratoconjunctivitis. (Eric M White, 2008) A viable combination therapy that increases convenience that promotes patient adherence. (Karpecki, 2021) Demonstrates high rates of bacterial eradication in patients with bacterial conjunctivitis (94.3–98.5%) and blepharoconjunctivitis (88.9%). (Karpecki, 2021) A well-tolerated agent in pediatric populations 0 to 6 years of age with blepharitis or blepharoconjunctivitis. (Karpecki, 2021) A safer therapeutic option for ocular inflammation that carries a risk of superficial bacterial infections. (Timothy L Comstock E. J., 2010) Protects against infection after surgery as well as treats existing infections by eradicating susceptible organisms. (Karpecki, 2021) An efficacious drug in a range of inflammatory ocular conditions along with a safety profile including a low risk of intraocular pressure elevation. (James E Deom, 2022) Provides coverage against a broad spectrum of common ocular pathogens. (James E Deom, 2022) A suitable treatment option for blepharitis, including that caused by a staphylococcal infection. (Karpecki, 2021) An appropriate treatment for other ocular surface inflammatory conditions that carry a risk of infection, such as contact lens-induced red eye. (Karpecki, 2021) A potent therapeutic option that is effective in reducing the signs of blepharitis. (Timothy L Comstock, 2017) Demonstrates a favorable safety profile than dexamethasone 0.1%/tobramycin 0.3% ophthalmic suspensions in blepharitis subjects. (Timothy L Comstock, 2017)
Headache, Burning sensation in the eye, Swelling of your face, lips, tongue, or throat, Blurred vision, Increased intraocular pressure
Blepharokeratoconjunctivitis , Bacterial Conjunctivitis , Allergic Conjunctivitis , Uveitis , Keratitis , Blepharitis
Temp data
Storage Condition
Product details for storage condition Product details for storage condition Product details for storage condition Product details for storage condition
Similar Products
No products found.
Send Enquiry
Request a callback to get more information about becoming a PCD Franchise Owner